See more : The J. M. Smucker Company (JM2.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Precigen, Inc. (PGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Adevinta ASA (ADEO.OL) Income Statement Analysis – Financial Results
- Doosan Robotics Inc. (454910.KS) Income Statement Analysis – Financial Results
- TB SA Acquisition Corp (TBSAW) Income Statement Analysis – Financial Results
- Autobacs Seven Co., Ltd. (9832.T) Income Statement Analysis – Financial Results
- e-LogiT co.,ltd. (9327.T) Income Statement Analysis – Financial Results
Precigen, Inc. (PGEN)
About Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.23M | 26.91M | 103.87M | 103.18M | 90.72M | 160.57M | 230.98M | 190.93M | 173.61M | 71.93M | 23.76M | 13.93M | 8.01M |
| Cost of Revenue | 6.12M | 6.34M | 58.39M | 55.51M | 61.40M | 63.29M | 62.79M | 61.64M | 63.93M | 19.26M | 48.17M | 64.03M | 0.00 |
| Gross Profit | 106.00K | 20.57M | 45.49M | 47.67M | 29.32M | 97.29M | 168.19M | 129.29M | 109.68M | 52.67M | -24.41M | -50.11M | 8.01M |
| Gross Profit Ratio | 1.70% | 76.44% | 43.79% | 46.20% | 32.32% | 60.59% | 72.82% | 67.72% | 63.18% | 73.22% | -102.71% | -359.85% | 100.00% |
| Research & Development | 48.61M | 47.17M | 50.14M | 41.64M | 101.88M | 404.59M | 143.21M | 112.14M | 147.48M | 58.98M | 48.17M | 64.19M | 70.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.42M | 48.01M | 74.12M | 91.70M | 100.84M | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 18.30M |
| Other Expenses | 0.00 | 1.54M | -330.00K | -165.00K | 3.45M | 630.00K | 1.01M | 1.70M | 1.31M | -168.00K | -162.00K | -101.00K | -1.00K |
| Operating Expenses | 84.18M | 95.18M | 124.26M | 133.35M | 202.72M | 542.39M | 289.31M | 254.45M | 256.54M | 122.63M | 81.78M | 89.08M | 90.44M |
| Cost & Expenses | 95.15M | 101.52M | 182.65M | 188.86M | 264.12M | 605.68M | 352.10M | 316.09M | 320.47M | 141.89M | 81.78M | 89.08M | 90.44M |
| Interest Income | 3.24M | 133.00K | 1.62M | 2.45M | 3.87M | 19.08M | 19.49M | 10.19M | 1.88M | 806.00K | 166.00K | 5.00K | 0.00 |
| Interest Expense | 468.00K | 6.77M | 18.89M | 18.40M | 17.67M | 8.53M | 611.00K | 861.00K | 1.24M | 666.00K | 141.00K | 57.00K | 183.00K |
| Depreciation & Amortization | 6.67M | 7.19M | 8.14M | 15.04M | 16.14M | 24.11M | 31.15M | 24.57M | 17.74M | 10.42M | 7.21M | 7.98M | 4.34M |
| EBITDA | -89.23M | -66.00M | -84.07M | -70.41M | -137.46M | -349.06M | -97.94M | -168.72M | -67.99M | -74.64M | -33.56M | -73.83M | -80.76M |
| EBITDA Ratio | -1,433.35% | -267.84% | -74.60% | -81.93% | -185.73% | -272.15% | -49.75% | -70.39% | -87.91% | -103.69% | -247.44% | -485.08% | -974.54% |
| Operating Income | -88.92M | -74.61M | -78.78M | -85.68M | -173.40M | -505.61M | -137.89M | -125.17M | -146.86M | -69.96M | -58.02M | -75.16M | -82.43M |
| Operating Income Ratio | -1,428.48% | -277.25% | -75.84% | -83.04% | -191.14% | -314.88% | -59.70% | -65.56% | -84.60% | -97.26% | -244.20% | -539.73% | -1,028.67% |
| Total Other Income/Expenses | -7.44M | -5.36M | -19.56M | -18.35M | -35.29M | -26.25M | 17.80M | -68.99M | 59.89M | -15.76M | 17.12M | -6.72M | -2.85M |
| Income Before Tax | -96.36M | -79.97M | -96.93M | -103.86M | -208.69M | -536.23M | -129.70M | -194.15M | -86.98M | -85.72M | -40.91M | -81.87M | -85.28M |
| Income Before Tax Ratio | -1,547.98% | -297.17% | -93.31% | -100.66% | -230.03% | -333.95% | -56.15% | -101.69% | -50.10% | -119.17% | -172.17% | -587.96% | -1,064.27% |
| Income Tax Expense | -458.00K | -189.00K | -160.00K | -82.00K | -930.00K | -21.53M | -2.88M | -3.88M | 1.02M | -103.00K | -9.76M | -318.00K | 182.00K |
| Net Income | -95.90M | -79.78M | -96.77M | -103.77M | -207.76M | -509.34M | -117.02M | -186.61M | -84.49M | -81.82M | -38.98M | -81.87M | -85.28M |
| Net Income Ratio | -1,540.63% | -296.47% | -93.16% | -100.58% | -229.00% | -317.20% | -50.66% | -97.74% | -48.67% | -113.75% | -164.06% | -587.96% | -1,064.27% |
| EPS | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| EPS Diluted | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| Weighted Avg Shares Out | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
| Weighted Avg Shares Out (Dil) | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen Reports First Quarter 2022 Financial Results and Business Updates
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia
PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports